GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Circio Holding ASA (OSL:CRNA) » Definitions » Other Operating Expense

Circio Holding ASA (OSL:CRNA) Other Operating Expense : kr419.87 Mil (TTM As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Circio Holding ASA Other Operating Expense?

Circio Holding ASA's Other Operating Expense for the three months ended in Dec. 2023 was kr0.00 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 was kr419.87 Mil.

Circio Holding ASA's quarterly Other Operating Expense declined from Dec. 2022 (kr407.94 Mil) to Jun. 2023 (kr0.00 Mil) but then stayed the same from Jun. 2023 (kr0.00 Mil) to Dec. 2023 (kr0.00 Mil).

Circio Holding ASA's annual Other Operating Expense increased from Dec. 2021 (kr54.02 Mil) to Dec. 2022 (kr451.35 Mil) but then declined from Dec. 2022 (kr451.35 Mil) to Dec. 2023 (kr45.36 Mil).


Circio Holding ASA Other Operating Expense Historical Data

The historical data trend for Circio Holding ASA's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Circio Holding ASA Other Operating Expense Chart

Circio Holding ASA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 61.70 51.74 54.02 451.35 45.36

Circio Holding ASA Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Dec23
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.78 11.93 407.94 - -

Circio Holding ASA Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr419.87 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Circio Holding ASA Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Circio Holding ASA's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Circio Holding ASA (OSL:CRNA) Business Description

Traded in Other Exchanges
Address
Vollsveien 19, Lysaker, Oslo, NOR, 1366
Circio Holding ASA is a clinical-stage company. It is focused on developing and commercializing immuno-oncology therapies to target treatment-resistant solid tumors. Its product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to infect cancer cells and activate the immune system to fight cancer. It includes the development and implementation with the purpose of developing targeted immunotherapy treatments for cancer patients.

Circio Holding ASA (OSL:CRNA) Headlines

No Headlines